Soon, 'insulin pill' may replace painful needle jabs

Scientists, including those of Indian origin, are developing an 'insulin pill' that could transform how diabetics manage their blood sugar levels, potentially spelling an end for painful injections.

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill.

However, for millions of people living with Type-1 diabetes, a painful needle prick once or twice daily is the only option for delivering the insulin that their bodies cannot produce on their own.

Insulin therapy, by injection just under the skin or delivered by an insulin pump, generally keeps the glucose levels of most diabetics in check.

"But many people fail to adhere to that regimen due to pain, phobia of needles, and the interference with normal activities," said Samir Mitragotri, a professor at Harvard John A Paulson School of Engineering and Applied Sciences (SEAS).

"The consequences of the resulting poor glycemic control can lead to serious health complications," said Mitragotri.

Finding a way to deliver insulin orally has been elusive; the protein does not fare well when it encounters the stomach's acidic environment and it is poorly absorbed out of the intestine.

The key to the new approach is to carry insulin in an ionic liquid comprised of choline and geranic acid that is then put inside a capsule with an acid-resistant enteric coating.

The formulation is biocompatible, easy to manufacture and can be stored for up to two months at room temperature without degrading, which is longer than some injectable insulin products currently on the market.

"Once ingested, insulin must navigate a challenging obstacle course before it can be effectively absorbed into the bloodstream," said Mitragotri.

"Our approach is like a Swiss Army knife, where one pill has tools for addressing each of the obstacles that are encountered," he said.

By encapsulating the insulin-ionic liquid formulation in an enteric coating, the team overcame the first obstacle, resisting breakdown by gastric acids in the gut.

This polymer coating dissolves when it reaches a more alkaline environment in the small intestine, where the ionic liquid carrying insulin is released.

"When a protein molecule such as insulin enters the intestine, there are many enzymes whose function is to degrade the proteins into smaller amino acids," said Amrita Banerjee, who conducted the research while working as a postdoctoral fellow in Mitragotri's lab.

"But the ionic liquid-borne insulin remains stable," said Banerjee, who is now an assistant professor at North Dakota State University

The choline-geranic acid formulation also was shown to be adept at penetrating two final barriers - the layer of mucus lining the intestine and the tight cell junctions of the intestine wall, through which large-molecule drugs such as insulin cannot easily pass.

Other researchers have tried various means of surmounting these barriers - by re-engineering the insulin molecule, coating it in protective polymers, and introducing additives to inhibit breakdown by enzymes or to enhance absorption.

However, no oral insulin delivery product is currently available in the clinic.

Orally ingested insulin would more closely mimic the way in which a healthy individual's pancreas makes and delivers insulin to the liver, where up to 80% is extracted and the rest is circulated through the bloodstream.

It could also mitigate the adverse effects of taking injections over a long period of time.